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ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many
chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer. A significant
association between common single nucleotide polymorphisms (SNPs) in ABCB1 and progression-free
survival has been reported in patients with ovarian cancer. Variable paclitaxel clearance due to genotype
specific differences in ABCB1 activity in cancer cells and/or normal tissues may underlie the association.
Using cell-based models, we evaluated the correlations between ABCB1 expression, polymorphisms,
transporter activity and paclitaxel sensitivity in ovarian cancer (n 5 10) and lymphoblastoid (n 5 19) cell
lines. Close associations between ABCB1 expression, transporter function and paclitaxel sensitivity were
found in lymphoblastoid cell lines, although we could not demonstrate an association with common SNPs.
In ovarian cancer cell lines, ABCB1 expression was low and the association between expression and function
was lost. These results suggest that ABCB1 related survival difference in ovarian cancer patients is more
likely to be due to differential whole body paclitaxel clearance mediated by normal cells rather than a direct
effect on cancer cells.
O
varian cancer is the seventh leading cause of cancer mortality among women globally. Most patients are
treated with paclitaxel and carboplatin chemotherapy after surgery1. However, chemotherapy response
varies widely between individuals. While a number of factors including tumor histology, somatic
mutations, environmental and drug-drug interactions, can contribute to the inter-individual variability, inherited
genetic variations are increasingly understood to influence drug disposition and activity.
Polymorphisms in genes encoding drug transporter proteins are among the most clinically important geno-
typic variations that may impact on therapeutic agents2. The adenosine triphosphate (ATP)-binding cassette
(ABC) transporter, ABCB1, also known as permeability-glycoprotein (P-gp) or multidrug resistance protein 1
(MDR1), is expressed in normal barrier tissues such as the apical membrane of intestine, the canalicular site of
hepatocytes, tubular cells of the kidney, lymphocytes, and also various human cancers3. It mediates the rapid exit
of a vast spectrum of therapeutic agents from cells including the chemotherapeutic drug paclitaxel4. A number of
studies have explored the potential of using ABCB1 polymorphisms as a predictive and/or prognostic marker in
ovarian cancer, but no compelling or consistent results have been identified5–7. Several factors including patient
numbers, study design and analytical methods may cause this discrepancy. In a cohort of 309 patients from the
Australian Ovarian Cancer Study (AOCS), we found three common single nucleotide polymorphisms (SNPs) in
ABCB1 (C1236T (rs1128503), G2677T/A (rs2032582) and C3435T (rs1045642)) were associated with significant
differences in progression-free survival (PFS) for the subgroup of women with # 1 cm residual disease who
received paclitaxel and carboplatin first-line chemotherapy. In this subgroup of patients, PFS was significantly
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carriers (HZ5 0.61, 95% CI 0.45–0.83; p5 0.002)8. A similar effect
was demonstrated in 281 patients from Scottish Randomised Trial in
Ovarian Cancer 1 (SCOTROC1) who had no residual disease after
surgery and received carboplatin and paclitaxel or docetaxel com-
bination chemotherapy8. On the basis of these findings, we hypothe-
sised that the association between ABCB1 genotype and outcome in
ovarian cancer may reflect differential cellular transport of paclitaxel
in normal and/or cancer cells.
To investigate this, we used cell-based models to evaluate the
associations between ABCB1 genetic polymorphisms, gene express-
ion, transporter activity and paclitaxel sensitivity in both ovarian
cancer cell lines and lymphoblastoid cell lines (LCLs) derived from
women with ovarian cancer. We reasoned that ovarian cancer cells
have multiple and varied genomic and phenotypic alterations that
may outweigh any effect of inherited polymorphisms, whereas
phenotype-genotype associations may be better appreciated in nor-
mal cells such as lymphoblastoid cell lines.
Results
ABCB1 expression was variable but higher in lymphoblastoid cell
lines compared with ovarian cancer cells. Relative levels of ABCB1
mRNA expression were determined in 19 LCLs and 10 ovarian
cancer cell lines. There was a 20-fold inter-individual variation in
ABCB1 expression in LCLs (Figure 1a). ABCB1 expression was also
variable in ovarian cancer cells although the level of ABCB1
expression in these cells was very low (Figure 1b).
LCLs eliminated paclitaxel faster than ovarian cancer cell lines. To
examine ABCB1 transporter activity, cellular bodipy-FL-paclitaxel
accumulation and efflux were measured in 13 LCLs and six ovarian
cancer cell lines selected to cover the spectrum of ABCB1 expression
and paclitaxel sensitivity, using flow cytometry. For these experi-
ments, a range of concentrations of bodipy-FL-paclitaxel was
tested and 0.1 mM was selected as it allowed rapid accumulation
and a steady state level of bodipy-FL-paclitaxel that was able to be
measured reproducibly by flow cytometry, but had no obvious effect
on cell viability during the short exposure time. Following incubation
with 0.1 mMbodipy-FL-paclitaxel, intracellular fluorescence activity
reached a steady state in both cell types after 30minutes (Supplemen-
tary Figure 1a). Under these conditions, we found no difference in
median intracellular bodipy-FL-paclitaxel fluorescence activity
between LCLs and ovarian cancer cells (Figure 2a).
Cellular bodipy-FL-paclitaxel fluorescence intensity decreased
over the efflux period (Figure 2b) and exhibited a three-phase elim-
ination pattern - an initial rapid efflux phase in the first three to five
minutes, followed by a slower efflux phase up to 15 minutes, usually
reaching a plateau phase between 15 to 30 minutes (Supplementary
Figures 1b & 1c). The presence of an ABC transporter blocker (ver-
apamil) significantly reduced bodipy-FL-paclitaxel efflux rate in all
cell lines, both LCLs (n 5 13) and ovarian cancer cell lines (n 5 6),
providing supporting evidence that bodipy-FL-paclitaxel efflux was
mediated by the ABCB1 transporter (representative examples shown
in Supplementary Figures 1d–1f).
A fitted curve and an efflux constant KE were generated for each
cell line based on a three compartment model using the solver func-
tion of Microsoft Excel (Figure 2c). The median efflux KE was sig-
nificantly higher in LCLs compared to ovarian cancer cell lines (0.470
vs 0.124, p5 0.011) in an independent median test, indicating more
rapid efflux of paclitaxel from LCLs (Figure 2d). The range of vari-
ation in efflux constant KE in LCLs (3.6-fold) and ovarian cancer cell
lines (3.2-fold) was similar.
ABCB1 expression was correlated with paclitaxel accumulation
and efflux in LCLs. The relationships between ABCB1 mRNA
relative expression, bodipy-FL-paclitaxel accumulation and efflux
constant KE were assessed in a correlation matrix by Spearman or
Pearson correlation tests depending on data distribution. In LCLs,
there was an inverse correlation between ABCB1 expression and
intracellular bodipy-FL-paclitaxel accumulation (Rs 5 20.571, p
5 0.041), and a positive correlation between ABCB1 expression
and the efflux constant kE (Rs 5 0.593, p 5 0.033) (Table 1).
Paclitaxel accumulation correlated strongly with efflux (R 5 0.748,
p5 0.003). These results indicated that LCLs expressing higher levels
of ABCB1 accumulated less intracellular paclitaxel and eliminated
paclitaxel more efficiently.
In contrast, there was no correlation between ABCB1 expression
and paclitaxel accumulation or efflux in ovarian cancer cell lines
(Table 1).
Ovarian cancer cell lines were more resistant to paclitaxel with a
wider variation in IC50. The cytotoxicity of paclitaxel was measured
in 19 LCLs and 10 ovarian cancer cell lines (Figure 3). There was a 10-
fold variation in paclitaxel IC50 among ovarian cancer cell lines.
PEO14 was the most paclitaxel resistant cell line with an IC50 of
15.0 nM, while CAOV-3 the most sensitive with a IC50 of 1.5 nM.
Figure 1 | Relative ABCB1 expression in lymphoblastoid and ovarian cancer cell lines.ABCB1mRNA expression wasmeasured by quantitative RT-PCR
in (a) 19 lymphoblastoid cell lines and (b) 10 ovarian cancer cell lines. All results were expressed relative to the level expressed in OVCAR-3. The
expression in SK-OV-3, A2780 and OVCAR-3 in (a) were measured in parallel to compare the levels of relative expression between lymphoblastoid cell
lines and ovarian cancer cell lines. The results presented were the geometricmean of values normalized to the three control genesHPRT,GUSB and PGK1.
www.nature.com/scientificreports
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LCLs were generally more sensitive to paclitaxel and had a much
smaller (2.4-fold) variation in paclitaxel IC50, ranging from 2.9 to
6.8 nM.
Paclitaxel toxicity correlated with efflux in lymphoblastoid cell
lines. In simple linear regression analysis, there was a trend of
correlation between ABCB1 expression and paclitaxel IC50 (r 5
0.429, p 5 0.067) (Figure 4a) and a trend of inverse correlation
between paclitaxel accumulation and toxicity (r 5 20.546, p 5
0.053) (Figure 4c) in LCLs. The correlation between paclitaxel
efflux constant kE and paclitaxel IC50 was strongly positive (r 5
0.819, p 5 0.001) (Figure 4e), demonstrating that LCLs that
eliminated paclitaxel more efficiently were more resistant to
paclitaxel. In multiple linear regression analysis, paclitaxel efflux
constant KE was the only independent variable strongly correlating
with paclitaxel IC50 (Beta coefficient 5 0.945, p 5 0.009) (Table 2).
There were no associations between paclitaxel cytotoxicity and
accumulation or efflux in ovarian cancer cell lines (Figures 4b, 4d
Figure 2 | Cellular accumulation and efflux of bodipy-FL-paclitaxel, a fluorescent ABCB1 substrate in lymphoblastoid and ovarian cancer cell lines
measured by flow cytometry. (a)Median bodipy-FL-paclitaxel accumulated in 13 LCLs and six ovarian cancer cell lines, by independent-samples median
test; (b) Decreasing bodipy-FL-paclitaxel fluorescence intensity over a 10 minutes efflux time, in one LCL as a representative example; (c) A fitted curve
generated by Solve function of Excel as compared to the actual curve of percentage fluorescence retained, in one LCL as a representative example;
(d)Median efflux constant KE in LCLs and ovarian cancer cell lines, by independent-samples median test. All results are mean of at least two independent
experiments.
Table 1 | Correlation matrix between ABCB1 relative expression, bodipy-FL-paclitaxel accumulation and efflux constant KE in lympho-
blastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test
Lymphoblastoid cell lines Ovarian cancer cell lines
ABCB1 Paclitaxel Paclitaxel ABCB1 Paclitaxel Paclitaxel
expression accumulation efflux expression accumulation efflux
ABCB1 expression Spearman correlation 1 20.571 0.593 1 20.086 0.086
p value 0.041 0.033 0.872 0.872
Paclitaxel accumulation Pearson correlation 20.571 1 0.748 20.086 1 0.100
p value 0.041 0.003 0.872 0.850
Paclitaxel efflux Pearson correlation 0.593 0.748 1 0.086 0.100 1
p value 0.033 0.003 0.872 0.850
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4669 | DOI: 10.1038/srep04669 3
and 4f and Table 2). Exploratory analyses were performed in three
ovarian cancer cell lines with relatively high ABCB1 expression
(ES-2, MDAH2774 and CAOV-3). Although there was trend of cor-
relation between ABCB1 expression and paclitaxel IC50, it was not
statistically significant (p5 0.206). There was no association between
efflux, accumulation and paclitaxel IC50, but the very small sample
number (n 5 3) limited the interpretation of these results.
No associations between ABCB1 genotype and paclitaxel
cytotoxicity or ABCB1 expression and transporter activity were
identified.CommonABCB1 SNPswere examined in all cell lines. No
associations were observed between SNPs inABCB1 exon 12 (C1236T),
21 (G2677T/A) and 26 (C3435T) and ABCB1 expression (Supple-
mentary Figure 2), paclitaxel accumulation, efflux or cytotoxicity in
LCLs or ovarian cancer cell lines (Jonckheere-Terpstra test for
ordered alternatives) (Figure 5).
Discussion
Several studies have suggested an association between ABCB1 geno-
types and clinical outcome in cancer patients9–11, including ovarian
cancer5,8,11,12. To investigate whether this association reflected differ-
ences in ABCB1 mediated transport of paclitaxel in normal or
ovarian cancer cells, we compared ABCB1 expression, paclitaxel
efflux, cytotoxicity and polymorphisms in normal and ovarian can-
cer cell lines under the same experimental conditions. In LCLs there
was a clear association between ABCB1 expression levels, the rate of
paclitaxel efflux and cytotoxicity. ABCB1 is responsible for the apical
transport of various chemotherapeutic agents like paclitaxel. The
degree of expression and the functionality of the transporter can
directly affect the intracellular concentration of paclitaxel, therefore
its growth inhibitor effects. As a result, more efficient efflux and
higher relative ABCB1 expression can lead to higher paclitaxel
IC50. In contrast, ABCB1 expression in ovarian cancer cells was very
low and not associated with paclitaxel efflux or cytotoxicity.
ABCB1 transporters are expressed and functionally active in all
peripheral blood cells, except in granulocytes13. The efficient efflux of
chemotherapeutic agents in peripheral blood and haematopoietic
cells may confer a degree of protection to these cell types. This find-
ing is consistent with the observations of pioneers such as Skipper
and Schabel, who found that some cancer cells recoveredmore slowly
(or not at all) compared to the more robust non-cancer cells when
incubated together in a high concentration of cytotoxic drugs for
hours or days, followed by longer periods of recovery14.
We found no apparent association between ABCB1 SNPs and
expression, efflux or cytotoxicity in LCLs. This is in contrast with
the study of 31 healthy Caucasian volunteers by Hitzl et al., which
reported a significant correlation between ABCB1 genotypes at posi-
tion 3435 with the efflux of rhodamine, an ABCB1 substrate, from
freshly isolated CD561 natural killer cells15. They also demonstrated
a correlation between genotype andmRNA expression in leukocytes.
Specifically these investigators reported that subjects who were
homozygous CC at position 3435 had faster rhodamine efflux from
CD561 natural killer cells and higher ABCB1 mRNA expression in
leukocytes than subjects with the TT genotype. More recently Wong
et al. reported that ABCB1 genotype was associated with hepatic
elimination of ABCB1 substrate technetium Tc99m-labeled sesta-
mibi in a cohort of cancer patients16. In their study, patients with
CC genotype at position 3435 of ABCB1 gene had faster hepatic
sestamibi clearance thanTT genotype. These data indicated potential
genotype related differences in ABCB1 function, which are consist-
ent with our clinical findings in ovarian cancer patients showing
women with CC genotype at position 3435 had worse PFS8.
Limitations of this study to detect an association between ABCB1
genotype and paclitaxel effect in normal cells include low levels of
absolute ABCB1 expression in LCLs, compared to liver and bowel;
the relatively small number of LCLs examined (n 5 19), and the
potential impact of exogenous factors during the process of EBV-
transformation and in vitro growth that may modify the phenotypes
compared with in vivo analyses.
ABCB1 is over-expressed in tumors that originate from tissues
expressing physiologically high levels of ABCB1 such as adrenal
gland, kidney, liver and colon17. In cell lines derived from these
tumors, an inverse correlation between ABCB1 expression and sen-
sitivities to chemotherapeutic drugs that are substrates of ABCB1
transport has been observed18–20. Consistent with the reported low
level expression in normal ovaries and untreated epithelial ovarian
cancer3,21, we found ABCB1 was expressed at very low levels in the
panel of 10 ovarian cancer cell lines. The presence of verapamil, an
ABCB1 blocker, inhibited paclitaxel efflux in all ovarian cancer cell
lines tested regardless of the level of ABCB1 expression, suggesting
ABCB1 transporter is functional in all ovarian cancer cell lines.
Despite the lower levels of ABCB1 expression and less efficient
paclitaxel elimination, some ovarian cancer cell lines were more
resistant to paclitaxel than LCLs. Ovarian cancer cells have multiple
genomic alterations and the loss of association between ABCB1
expression, paclitaxel elimination and paclitaxel resistance could
Figure 3 | Inhibition of proliferation by paclitaxel in lymphoblastoid and ovarian cancer cell lines. Effect of paclitaxel on cell proliferation wasmeasured
in (a) 19 lymphoblastoid cell lines and (b) 10 ovarian cancer cell lines using the CellTitre AQueous One Solution Cell Proliferation Assay, measured after
72 hrs drug exposure, represented as a percentage of vehicle treated control. Results are mean with standard error of mean of three independent
experiments performed in triplicate.
www.nature.com/scientificreports
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Figure 4 | Relationship between growth inhibitory effects of paclitaxel, ABCB1 expression and cellular drug accumulation and efflux. Paclitaxel growth
inhibitory effect (IC50) was determined in 13 lymphoblastoid cell lines (a), (c) and (e) and 6 ovarian cancer cell lines (b), (d) and (f) by CellTitre AQueous
One Solution Cell Proliferation Assay after 72 hrs drug exposure. ABCB1 mRNA expression (a) and (b) was measured by RT-PCR and bodipy-FL-
paclitaxel accumulation (c) and (d) and efflux (e) and (f) were measured by flow cytometry. The correlation between paclitaxel IC50 and ABCB1
expression (a) and (b), paclitaxel IC50 and drug accumulation (c) and (d) and the correlation between IC50 and drug efflux constant KE (e) and (f) were
determined by simple linear regression analysis.
Table 2 | Multiple linear regression analysis of ABCB1 expression, bodipy-FL-paclitaxel accumulation, efflux and paclitaxel IC50
Lymphoblastoid cell lines Ovarian cancer cell lines
Unstandardized Standardized Unstandardized Standardized
coefficients coefficients coefficients coefficients
B SE Beta p B SE Beta p
ABCB1 expression 20.002 0.004 20.114 0.723 20.062 0.175 20.206 0.757
Paclitaxel accumulation 0.002 0.008 0.070 0.849 0.008 0.027 0.171 0.795
Paclitaxel efflux 4.851 1.456 0.945 0.009 249.444 52.27 20.535 0.444
www.nature.com/scientificreports
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be due to a variety of factors including somatic mutations22, onco-
gene expression and amplification or inappropriate growth factor
regulation23 in ovarian cancer cells. Other factors that could poten-
tially contribute to paclitaxel resistance despite low ABCB1 express-
ion in ovarian cancer cells, include alterations in tubulin binding
and dynamics due to tubulin mutation24, altered expression of
microtubule-associated proteins (MAP)25 and decreased sensitivity
to apoptosis-induced stimuli.
Genomic differences between cancer cell lines and tissue samples
have been pointed out in several studies22,26,27. So primary ovarian
cancer cells, freshly isolated from either solid tumor or malignant
ascites, may offer an experimental system that resembles the patient’s
Figure 5 | Association between growth inhibitory effects of paclitaxel and ABCB1 genotypes. Paclitaxel growth inhibitory effects (IC50) were
determined in 19 lymphoblastoid cell lines (a), (c) and (e) and 10 ovarian cancer cell lines (b), (d) and (f), by CellTitre AQueous One Solution Cell
Proliferation Assay after 72 hrs drug exposure. ABCB1 genotype was determined by iPLEX genotyping on Sequenom’s MassARRAY platform.
Associations between IC50 and ABCB1 genotypes at C1236T (a) and (b), G2677T/A (c) and (d) and C3435T (e) and (f) were analysed by Jonckheere-
Terpstra test.
www.nature.com/scientificreports
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situationmore closely. The ovarian cancer cell lines used in this study
were derived from tumors of various histological subtypes and carry
a variety of mutations22. Restricting analyses to cell lines with a
similar histological/genomic profile may yield a different result.
Although our study did not confirm the presence of an ABCB1
genotype-phenotype correlation in LCLs or ovarian cancer cell lines,
the strong association we found between ABCB1 expression, trans-
porter function and paclitaxel cytotoxicity in LCLs, together with the
very low levelABCB1 expression in the panel of 10 ovarian cancer cell
lines, suggests that the observed ABCB1 genotype-related outcome
differences in ovarian cancer patients is more likely to be due to
differential, whole body elimination of paclitaxel rather than a direct
effect on cancer tissues. Few studies published to date have assessed
the effects of ABCB1 genotypes on paclitaxel clearance in ovarian
cancer patients7,28,29, and the results have been contradictory. Possible
reasons include small patient numbers and significant variation in
paclitaxel dosage and infusion time. Our results suggest that further
detailed assessment of the effect of SNPs in ABCB1, and potentially
SNPs in other genes on paclitaxel clearance and ultimate association
with ovarian cancer survival is warranted.
Methods
Cell line authentication and culture conditions. EBV-transformed B-
lymphoblastoid cell lines (LCLs) from 19 Caucasian ovarian cancer patients were
obtained through the Australian Ovarian Cancer Study (AOCS)30. Human ovarian
cancer cell lines A2780, COLO316, JAM, PEO1, PEO14, OVCAR-3 (Professor
Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Australia),
CAOV-3, ES-2 and SK-OV-3 (ATCC, Manassas, VA, USA) were authenticated by
STR profiling (Promega Cell ID System, Promega Corporation, Madison WI, USA)
against published profiles. MDAH2774 was profiled, but no reference was available
for comparison.
LCLs and ovarian cancer cells were maintained in RPMI 1640 (Invitrogen
Corporation, Carlsbad CA, USA) supplemented with 15% and 10% fetal calf serum
(SAFC Biosciences, Lenexa KS, USA) v/v respectively. All cells were grown at 37uC in
a humidified atmosphere containing 5% CO2. Cells were tested regularly for
Mycoplasma contamination and shown to be negative.
This study was approved by the Western Sydney Local Health District and
Queensland Institute of Medical Research Human Research Ethics Committees, and
AOCS was approved by the Human Research Ethics Committees at the Peter
MacCallum Cancer Centre, Queensland Institute of Medical Research, University of
Melbourne and all participating hospitals. Methods were carried out in accordance
with the approved guidelines and informed consent was obtained from all subjects.
ABCB1 genotyping.Genomic DNA was extracted using DNeasy Blood & Tissue Kit
(Qiagen, Hilden, Germany). Common ABCB1 SNPs at exon 12 (C1236T), 21
(G2677T/A) and 26 (C3435T) were examined by iPLEX genotyping on Sequenom’s
MassARRAY platform8.
Expression of ABCB1 mRNA by real-time PCR. RNA was extracted using the
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). RNA was reverse transcribed
with MMLV reverse transcriptase (Life Technologies, Carlsbad CA, USA) as
previously described31. Real-time PCR quantitation of gene expression utilising
TaqManH gene expression assays (ABCB1, assay IDHs00184500 m1;GUSB, assay ID
4326320E; HPRT, assay ID 4326321E; PGK1, assay ID 4326318E) were conducted
using a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City CA,
USA). Gene expression levels were determined using theDDCtmethod and expressed
relative to a calibrator. Expression values were calculated as the geometric mean of
values normalized to the three control genes HPRT, GUSB and PGK1.
Paclitaxel growth inhibition assay. Drug concentrations that inhibited 50% of cell
growth (IC50) were determined using the CellTitre AQueous One Solution Cell
Proliferation Assay (Promega, Madison WI, USA). Briefly, cell suspensions (100 mL,
5000 cells for LCLs and 10000 cells for cancer cell lines) were plated in 96-well flat
bottom plates. After 24-h incubation, cells were treated with 50 ml of increasing
concentrations (0–15 nM) of paclitaxel injection solution (Sigma-Aldrich Inc, St
Louis MA, USA) and vehicle control (Cremophor ELTM and dehydrated ethanol USP
(151, v/v)) for 72 hours before adding 30 mL of MTS reagent. Following 3-h
incubation, absorbance at 490 nm was recorded on aWallac Victor2 1420 Multilabel
Counter (Perkin Elmer Life Sciences, Waltham, MA, USA). Percent survival was
quantified according to the manufacturer’s protocol. Paclitaxel IC50 was determined
by curve fitting of percentage cell survival against concentrations of paclitaxel. All
experiments were conducted at least three experiments in triplicate.
Bodipy-FL-paclitaxel accumulation and efflux assay.To allow bodipy-FL-paclitaxel
(Invitrogen, Carlsbad CA, USA) accumulation, cell suspensions at densities of 106
cells per mL were incubated with bodipy-FL-paclitaxel at a concentration of 0.1 mM
for 30 minutes at 37uC and 5% CO2. After accumulation, cells were aliquoted into
Eppendorf tubes (Eppendorf, Hamburg, Germany) (1 mL per tube) on ice,
centrifuged for 5minutes at 400 g at 4uC andwashed twice with ice old PBS to remove
extracellular bodipy-FL-paclitaxel.
After washing, the positive control sample was resuspended in 1 mL ice-cold
medium for the measurement of the baseline fluorescence using a FACSCanto flow
cytometer (488 nm, 20 mW laser; 530/30 band pass filter) (BD Biosciences, Franklin
Lakes, New Jersey, USA). The remaining samples were resuspended in 1 mL 37uC
medium and incubated at 37uC for 0.5, 1, 3, 5, 10, 15 and 30 minutes respectively to
allow paclitaxel efflux. Three samples were incubated in medium containing vera-
pamil (Abbott Australasia, Botany, Australia) at a concentration of 1 mg/mL for 5, 10
and 15 minutes respectively.
Appropriate threshold values were set to exclude clumps and debris, and samples
were gated on forward scatter vs side scatter to include lymphoblastoid or cancer cell
populations. A minimum of 10,000 events were collected per sample. Data was
expressed as median bodipy-FL-paclitaxel fluorescence. Bodipy-FL-paclitaxel fluor-
escence in control sample, after baseline dye uptake, was set as 100%. Bodipy-FL-
paclitaxel fluorescence in efflux samples, exposed to different efflux time periods, was
used to calculate the percentage of bodipy-FL-paclitaxel retained in the cells in
comparison with control.
Pharmacokinetic modelling of bodipy-FL-paclitaxel cellular elimination.
Intracellular paclitaxel fluorescence intensity is the combined result of active efflux
through ABCB1 transporter, passive diffusion/efflux through the cell membrane and
redistribution of the fluorescence frommedium into the cells at the late phase of efflux
assay. Hence a three compartment model was developed to reflect the changes. The
summation of the kinetics of intra-cellular fluorescence resulted in an exponential
equation of the following form: percentage of intra-cellular fluorescence at time t 5
Ae2kEt 1 Be2kDt 1 Ce2kRt, where A, B and C are constants; kE is the active efflux
constant; kD is the passive diffusion/efflux constant and kR is the redistribution
constant. This equation was derived from fluorescence data of cell lines by the use of
the solver function of Microsoft Excel (Office XP; Microsoft Corp, Redmond, Wash,
USA). The efflux constant (kE) was used as the measure of bodipy-FL-paclitaxel
cellular efflux rate and ABCB1 transporter activity.
Statistical analysis. Spearman or Pearson correlation tests were used to assess the
relationships between ABCB1 expression, bodipy-FL-paclitaxel accumulation and
efflux constant KE. Linear regression analysis was performed to assess their impacts
on paclitaxel IC50. Independent median test was used to compare the median bodipy-
FL-paclitaxel accumulation and efflux between LCLs and ovarian cancer cell lines.
Nonparametric Jonckheere-Terpstra test was used to compare the distribution of
ABCB1 expression, paclitaxel cytotoxicity and bodipy-FL-paclitaxel efflux constant
kE between cell lines of different genotypes. All calculations were performed with
SPSS forWindows v21 (SPSS, Chicago, Ill, USA). All tests are two-tailed and p-values
# 0.05 were considered to be of statistical significance.
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